Clinical Trials/NCT00072774

NCT00072774

Completed

Phase 3

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Three Fixed Doses (100 Mg, 200 Mg, Or 400 Mg) Of DVS-233 SR In Adult Outpatients With Major Depressive Disorder

Wyeth is now a wholly owned subsidiary of Pfizer0 sites480 target enrollmentNovember 13, 2003

ConditionsMajor Depressive Disorder

DrugsDVS-233 SR

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Major Depressive Disorder
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Enrollment: 480
Status: Completed
Last Updated: 16 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

To compare the antidepressant efficacy and safety of subjects receiving DVS-233 SR versus subjects receiving placebo.

Registry

clinicaltrials.gov

Start Date

November 13, 2003

End Date

November 2004

Last Updated

16 years ago

Study Type

Interventional

Study Design

Parallel

Sex

All

Investigators

Sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Eligibility Criteria

Inclusion Criteria

•Outpatients
•Sexually active women participating in the study must use a medically acceptable form of contraception
•Subjects must have a primary diagnosis of major depressive disorder

Exclusion Criteria

•Treatment with DVS-233 SR at any time in the past
•Treatment with venlafaxine (immediate release \[IR\] or extended release \[ER\]) within 90 days of study day 1
•Known hypersensitivity to venlafaxine (IR or ER)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Study Evaluating DVS-233 in Adult Outpatients With Major Depressive DisorderMajor Depressive Disorder

NCT00063206Wyeth is now a wholly owned subsidiary of Pfizer247

Study Evaluating DVS-233 SR In Adult Outpatients With Major Depressive DisorderMajor Depressive Disorder

NCT00073762Wyeth is now a wholly owned subsidiary of Pfizer375

Study Evaluating DVS-233 SR And Venlafaxine ER In Adult Outpatients With Major Depressive DisorderMajor Depressive Disorder

NCT00090649Wyeth is now a wholly owned subsidiary of Pfizer369

Study Evaluating DVS-233 SR in Adult Outpatients With Major Depressive DisorderDepressionDepressive DisorderMajor Depressive Disorder

NCT00092911Wyeth is now a wholly owned subsidiary of Pfizer244

Study Evaluating DVS-233 SR and Venlafaxine ER in Adult Outpatients With Major Depressive DisorderMajor Depressive Disorder

NCT00087737Wyeth is now a wholly owned subsidiary of Pfizer369